Literature DB >> 11145562

Transcriptional regulation of insulin-like growth factor-I receptor gene expression in prostate cancer cells.

S E Damon1, S R Plymate, J M Carroll, C C Sprenger, C Dechsukhum, J L Ware, C T Roberts.   

Abstract

A marked decrease in the type 1 insulin-like growth factor (IGF) receptor (IGF-IR) occurs in prostate epithelial cells during transformation from the benign to the metastatic state. One of the principal regulators of IGF-IR gene expression, the WT1 tumor suppressor, is expressed in prostate cancer and in prostate cancer cell lines. The purpose of this study was to determine whether the decrease in IGF-IR expression was transcriptionally regulated, and whether WT1 action may be involved in the repression of the IGF-IR gene in prostate cancer cells. The P69 cell line was derived by immortalization of human primary prostate epithelial cells with simian virus-40 T antigen and is rarely tumorigenic. The M12 line was derived from the P69 line by selection for tumor formation in nude mice and is tumorigeneic and metastatic. P69 cells express 20,000 IGF-IR/cell, whereas M12 cells express 3,500 IGF-IR/cell. These differences in receptor number are reflected in proportional differences in IGF-IR mRNA levels. To assess IGF-IR promoter activity in these cell lines, each was transiently transfected with luciferase reporter vectors containing the IGF-IR gene transcription start site and 476 bp of 5'-flanking sequence, 640 bp of 5'-untranslated region sequence, or both regions. The promoter activity of the full-length construct was 50% lower (P < 0.01) in M12 cells compared with P69 cells, the activity of the 5'-flanking region construct was 53% lower (P < 0.0001), and that of the 5'-untranslated region construct was 36% lower (P = 0.01). P69 clones stably transfected with a WT1 expression vector exhibited decreased expression of the endogenous IGF-IR gene and decreased promoter activity in transient transfection assays with IGF-IR promoter constructs containing multiple WT1 binding sites. The observed reduction in endogenous IGF-IR expression was sufficient to inhibit IGF-I-stimulated cell proliferation. These data suggest that most of the decreased expression of the IGF-IR seen in malignant prostate epithelium is the result of transcriptional repression of the IGF-IR gene, and that this repression may be due in part to the increased expression of the WT1 tumor suppressor in metastatic prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11145562     DOI: 10.1210/endo.142.1.7890

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  14 in total

Review 1.  Cancer.

Authors:  Adda Grimberg
Journal:  Adv Exp Med Biol       Date:  2005       Impact factor: 2.622

2.  Wilms' tumor 1 silencing decreases the viability and chemoresistance of glioblastoma cells in vitro: a potential role for IGF-1R de-repression.

Authors:  Mike Y Chen; Aaron J Clark; Dana C Chan; Joy L Ware; Shawn E Holt; Archana Chidambaram; Helen L Fillmore; William C Broaddus
Journal:  J Neurooncol       Date:  2010-09-04       Impact factor: 4.130

3.  Differential regulation of insulin-like growth factor-I receptor gene expression by wild type and mutant androgen receptor in prostate cancer cells.

Authors:  Hagit Schayek; Hila Seti; Norman M Greenberg; Shihua Sun; Haim Werner; Stephen R Plymate
Journal:  Mol Cell Endocrinol       Date:  2010-04-24       Impact factor: 4.102

Review 4.  Mechanisms by which IGF-I may promote cancer.

Authors:  Adda Grimberg
Journal:  Cancer Biol Ther       Date:  2003 Nov-Dec       Impact factor: 4.742

5.  Tumor suppressor BRCA1 is expressed in prostate cancer and controls insulin-like growth factor I receptor (IGF-IR) gene transcription in an androgen receptor-dependent manner.

Authors:  Hagit Schayek; Kathy Haugk; Shihua Sun; Lawrence D True; Stephen R Plymate; Haim Werner
Journal:  Clin Cancer Res       Date:  2009-02-17       Impact factor: 12.531

6.  IL-6 promotes prostate tumorigenesis and progression through autocrine cross-activation of IGF-IR.

Authors:  A Rojas; G Liu; I Coleman; P S Nelson; M Zhang; R Dash; P B Fisher; S R Plymate; J D Wu
Journal:  Oncogene       Date:  2011-01-24       Impact factor: 9.867

Review 7.  Targeting tyrosine kinases and autophagy in prostate cancer.

Authors:  Hsing-Jien Kung
Journal:  Horm Cancer       Date:  2010-12-02       Impact factor: 3.869

8.  The transcription factors Ik-1 and MZF1 downregulate IGF-IR expression in NPM-ALK⁺ T-cell lymphoma.

Authors:  Deeksha Vishwamitra; Choladda V Curry; Serhan Alkan; Yao-Hua Song; Gary E Gallick; Ahmed O Kaseb; Ping Shi; Hesham M Amin
Journal:  Mol Cancer       Date:  2015-02-25       Impact factor: 27.401

9.  Clinical significance of insulin-like growth factor-1 receptor expression in stage I non-small-cell lung cancer: immunohistochemical analysis.

Authors:  Chang Youl Lee; Jeong Hee Jeon; Hyung Jung Kim; Dong Hwan Shin; Tae Woong Roh; Chul Min Ahn; Yoon Soo Chang
Journal:  Korean J Intern Med       Date:  2008-09       Impact factor: 2.884

10.  The Wilms' tumour suppressor protein WT1 acts as a key transcriptional repressor of the human thromboxane A2 receptor gene in megakaryocytes.

Authors:  AnneMarie M Gannon; B Therese Kinsella
Journal:  J Cell Mol Med       Date:  2009 Nov-Dec       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.